Ditchcarbon
  • Contact
  1. Organizations
  2. DTx Pharma, Inc.
Public Profile
Research Pending

This profile hasn't yet passed our validation checks

Submit your email to push it up the queue

We'll prioritize this organization's research and notify you when detailed sustainability data becomes available.

Health Services
US
updated a day ago

DTx Pharma, Inc.

Company website

DTx Pharma, Inc., a pioneering biopharmaceutical company headquartered in the United States, is at the forefront of developing innovative therapies for patients with serious diseases. Founded in [year], DTx Pharma focuses on the discovery and advancement of novel drug candidates that leverage its proprietary platform for targeted delivery of therapeutics. With a strong emphasis on precision medicine, the company is dedicated to addressing unmet medical needs in areas such as oncology and rare diseases. DTx Pharma's unique approach combines cutting-edge technology with a commitment to improving patient outcomes, positioning it as a leader in the biopharmaceutical industry. Notable achievements include [key milestones], which underscore its rapid growth and market presence. As DTx Pharma continues to expand its operational reach, it remains committed to transforming the landscape of drug development.

DitchCarbon Score

How does DTx Pharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

100

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

23

Industry Benchmark

DTx Pharma, Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

100%

Let us know if this data was useful to you

DTx Pharma, Inc.'s reported carbon emissions

Inherited from Novartis AG

DTx Pharma, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family relationship with Novartis AG, which provides a framework for its climate commitments and initiatives. As a current subsidiary of Novartis AG, DTx Pharma inherits various sustainability initiatives and targets from its parent company. Novartis has established science-based targets (SBTi) aimed at reducing greenhouse gas emissions across its operations. These initiatives include commitments to the Carbon Disclosure Project (CDP), the RE100 renewable energy initiative, and the Race to Zero campaign, all of which are cascaded to DTx Pharma. While specific reduction targets for DTx Pharma are not detailed, the overarching goals set by Novartis reflect a commitment to sustainability and climate action. This includes a focus on reducing emissions across all scopes, although specific scope data for DTx Pharma is not available. In summary, while DTx Pharma, Inc. does not currently report its own emissions data, it aligns with the climate commitments and reduction initiatives of Novartis AG, which are designed to drive significant progress in reducing carbon emissions and promoting sustainability within the pharmaceutical industry.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201020112012201320142015201620172018201920202021202220232024
Scope 1
583,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 2
922,000,000
0,000,000,000
0,000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
00,000,000
Scope 3
-
-
000,000,000
000,000,000
000,000,000
000,000,000
-
000,000,000
000,000,000
000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. DTx Pharma, Inc.'s primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for DTx Pharma, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

DTx Pharma, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251008.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy